The study, published March 23 in JAMA Network Open, followed 3,850 patients with a type of pancreatic cancer known as pancreatic ductal adenocarcinoma. Participants were given either first-line gemcitabine or fluorouracil.
Researchers found those who received gemcitabine had 11 percent higher survival rates and 16 percent improvement in cancer-specific survival. There was no association between antibiotic treatment and survival for those given fluorouracil.
The study has not been peer reviewed.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
